ZURICH: Swiss drugmaker Novartis (NOVN.S) said on Sunday it has agreed to acquire U.S. biotech firm Avidity Biosciences (RNA.O) in a deal valued at approximately $12 billion, expanding its reach into the promising field of RNA therapeutics. Under the terms of the agreement, Novartis will pay $72 per share in cash for Avidity, representing…
LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024. The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM…